A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

January 4, 2030

Study Completion Date

January 4, 2030

Conditions

Generalized Myasthenia Gravis

Interventions

DRUG

Inebilizumab

Inebilizumab will be administered IV.